NCT03580564View on ClinicalTrials.gov

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 22, 2020

Study Completion Date

January 13, 2022

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG

KL-A167

KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY

NCT03580564 - An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter